Fortrea Holdings is trading 5.05% down now at $17.68, with stronger employment data and reduced rate-cut expectations potentially contributing to broader pressure.
- No clear company-specific negative catalyst was identified for September 4, 2026.
- Fortrea’s recently announced $45 million acquisition of Worldwide Clinical Trials’ Early Phase Services division was previously associated with a positive share reaction, not today’s decline.
- The broader market move is moderate.